Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2018-08-23
|
| gptkbp:ATCCode |
B06AC05
|
| gptkbp:CASNumber |
1333466-37-4
|
| gptkbp:form |
solution for injection
prefilled syringe |
| gptkbp:genericName |
lanadelumab
|
| gptkbp:halfLife |
14 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
Takhzyro
|
| gptkbp:indication |
gptkb:hereditary_hemorrhagic_telangiectasia
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
gptkb:monoclonal_antibody
|
| gptkbp:manufacturer |
gptkb:Takeda_Pharmaceuticals
|
| gptkbp:mechanismOfAction |
plasma kallikrein inhibitor
|
| gptkbp:pregnancyCategory |
not assigned
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
headache
injection site reaction upper respiratory infection |
| gptkbp:storage |
2°C to 8°C
|
| gptkbp:bfsParent |
gptkb:Takeda
gptkb:Takeda_(Japan) |
| gptkbp:bfsLayer |
6
|